Here’s a roundup of the most significant insider transactions disclosed on Friday, November 21, 2025.
Top Buys
STAAR Surgical Co (NASDAQ:STAA) saw substantial insider buying from Broadwood Partners and Neal C. Bradsher, who reported purchasing shares worth over $41 million between November 19 and November 21, 2025. The buying activity occurred in multiple tranches: 309,132 shares at an average price of $26.42 on November 19, followed by 393,382 shares at an average price of $27.14 on November 20, with prices ranging from $26.56 to $27.35. The buying continued on November 21 with the purchase of 797,486 shares at an average price of $27.86, with prices ranging from $27.30 to $28.23.
Annovis Bio, Inc. (NASDAQ:ANVS) Director Michael B Hoffman reported purchasing a total of 20,000 shares on November 21, 2025. The director acquired the shares in two equal transactions of 10,000 shares each, at prices ranging from $3.49 to $3.50, for a total investment of $69,900. Following these purchases, Hoffman directly owns 2,490,539 shares and indirectly owns an additional 223,357 shares through The 2018 Jane and Michael Hoffman Descendants Trust. The purchases come amid a significant 61.97% stock price surge over the past week, with shares trading at $3.79. The company has been making progress in its clinical trials, with its Phase 3 study for early Alzheimer’s disease reaching 25% completion and all 84 U.S. clinical sites now fully activated and enrolling patients.
Hallador Energy Co (NASDAQ:HNRG) Director Wesley Charles Ray IV purchased 13,000 shares of common stock on November 21, 2025, at a price of $19.28 per share, for a total transaction value of $250,664. Following this transaction, Wesley directly owns 91,270 shares, while the Charles R. Wesley IV Revocable Trust indirectly holds an additional 247,914 shares of Hallador Energy.
Butterfly Network, Inc. (NASDAQ:BFLY) Director Larry Robbins acquired a substantial 2,800,000 shares of Class A Common Stock across three separate transactions between November 19 and November 21, 2025. The purchases were made at prices ranging from $2.35 to $2.58 per share, representing a total investment of $6,784,060. This significant insider buying comes as BFLY shares, currently trading at $2.65, have posted a remarkable 25% return over the past week despite showing significant volatility with a beta of 2.36.
Texas Pacific Land Corp (NASDAQ:TPL) saw a symbolic purchase from ten percent owner Horizon Kinetics Asset Management LLC, which acquired 1 share of common stock at $918.95 on November 20, 2025. Following this transaction, Horizon Kinetics directly owns 1,162,570 shares of TPL. The purchase comes after Texas Pacific Land reported disappointing third-quarter earnings for 2025, with EPS of $5.27 missing analysts’ expectations of $5.69, and revenue of $203 million falling short of the forecasted $210 million.
Top Sells
Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 1,300,000 common shares on November 19, 2025, in multiple transactions with prices ranging from $20.16 to $20.25, for a total value of approximately $26.3 million. Following these transactions, Gold indirectly holds 18,047,727 shares through QVT Financial Investment Cayman Ltd. The sales occurred as Roivant shares trade near their 52-week high of $21.35, having delivered a 61% return over the past year.
Roivant Sciences Ltd. (NASDAQ:ROIV) Director Keith S. Manchester also sold 1,300,000 common shares on November 19, 2025, in a series of four separate transactions at prices ranging from $20.16 to $20.25, totaling approximately $26.3 million. The sales come as Roivant’s stock trades near its 52-week high of $21.35, having delivered an impressive 84.8% return over the past six months. At the current price of $20.23, Roivant Sciences commands a market capitalization of approximately $14.1 billion.
Roivant Sciences Ltd. (NASDAQ:ROIV) saw a third major seller in QVT Financial LP, a director by deputization, which disposed of 1,300,000 shares on November 19, 2025. The shares were sold in multiple transactions at prices ranging from $20.16 to $20.25, resulting in a total transaction value of $26.3 million. Following the reported transactions, QVT Financial LP is deemed to beneficially own 28,081,635 Common Shares held by QVT Financial Investment Cayman Ltd.
Precigen, Inc. (NASDAQ:PGEN) Director Randal J. Kirk sold 2,966,293 shares of common stock between November 19 and November 21, 2025, generating approximately $12.3 million. The sales were executed over three days: 1,086,153 shares at a weighted average price of $4.47 on November 19, 942,832 shares at a weighted average price of $4.08 on November 20, and 937,308 shares at $3.83 on November 21. The transactions come as PGEN has experienced a 20% decline over the past week, despite posting a remarkable 330% return over the last year.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ten percent owner Catalys Pacific Fund sold 1,000,000 shares of common stock on November 20, 2025, at a price of $43.35 per share, for a total transaction value of $43,350,000. Following the transaction, Catalys Pacific Fund retains ownership of 7,903,838 Mineralys Therapeutics shares. The sale occurred near MLYS’s current trading price of $41.85, with the stock having delivered an impressive 252% return over the past year and 151% over the last six months.
Why Monitor Insider Activity
Tracking insider transactions provides valuable insights into how company executives and major shareholders view their own stock’s prospects. When insiders buy shares with their own money, it often signals confidence in the company’s future performance. Conversely, insider selling may indicate that those with the most intimate knowledge of a company’s operations see limited upside potential or are diversifying their investments. While no single transaction should be used as the sole basis for investment decisions, patterns of insider activity can serve as one important factor in a comprehensive investment analysis strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
